Artemin is oncogenic for human mammary carcinoma cells

Show simple item record

dc.contributor.author Kang, Jian en
dc.contributor.author Perry, Johanna en
dc.contributor.author Pandey, Vijay en
dc.contributor.author Fielder, Graeme en
dc.contributor.author Mei, B en
dc.contributor.author Qian, PX en
dc.contributor.author Wu, ZS en
dc.contributor.author Zhu, T en
dc.contributor.author Liu, Dongxu en
dc.contributor.author Lobie, Peter en
dc.date.accessioned 2012-03-04T19:14:11Z en
dc.date.issued 2009-05-14 en
dc.identifier.citation Oncogene 28(19):2034-2045 14 May 2009 en
dc.identifier.issn 0950-9232 en
dc.identifier.uri http://hdl.handle.net/2292/12651 en
dc.description.abstract We report that artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is oncogenic for human mammary carcinoma. Artemin is expressed in numerous human mammary carcinoma cell lines. Forced expression of artemin in mammary carcinoma cells results in increased anchorage-independent growth, increased colony formation in soft agar and in three-dimensional Matrigel, and also promotes a scattered cell phenotype with enhanced migration and invasion. Moreover, forced expression of artemin increases tumor size in xenograft models and leads to highly proliferative, poorly differentiated and invasive tumors. Expression data in Oncomine indicate that high artemin expression is significantly associated with residual disease after chemotherapy, metastasis, relapse and death. Artemin protein is detectable in 65% of mammary carcinoma and its expression correlates to decreased overall survival in the cohort of patients. Depletion of endogenous artemin with small interfering RNA, or antibody inhibition of artemin, decreases the oncogenicity and invasiveness of mammary carcinoma cells. Artemin is therefore oncogenic for human mammary carcinoma, and targeted therapeutic approaches to inhibit artemin function in mammary carcinoma warrant consideration. Oncogene (2009) 28, 2034-2045; doi:10.1038/onc.2009.66; published online 13 April 2009 en
dc.description.uri http://www.nature.com/onc/journal/v28/n19/pdf/onc200966a.pdf en
dc.language EN en
dc.publisher NATURE PUBLISHING GROUP en
dc.relation.ispartofseries Oncogene en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0950-9232/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject artemin en
dc.subject GDNF en
dc.subject mammary en
dc.subject carcinoma en
dc.subject oncogenicity en
dc.subject NEUROTROPHIC FACTOR GDNF en
dc.subject PANCREATIC-CANCER CELLS en
dc.subject HUMAN GROWTH-HORMONE en
dc.subject BREAST-CANCER en
dc.subject STROMAL FIBROBLASTS en
dc.subject NEURONAL CELLS en
dc.subject NUDE-MICE en
dc.subject FAMILY en
dc.subject EXPRESSION en
dc.subject RECEPTOR en
dc.title Artemin is oncogenic for human mammary carcinoma cells en
dc.type Journal Article en
dc.identifier.doi 10.1038/onc.2009.66 en
pubs.issue 19 en
pubs.begin-page 2034 en
pubs.volume 28 en
dc.rights.holder Copyright: NATURE PUBLISHING GROUP en
dc.identifier.pmid 19363524 en
pubs.author-url http://www.nature.com/onc/journal/v28/n19/full/onc200966a.html en
pubs.end-page 2045 en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 85705 en
pubs.org-id Liggins Institute en
pubs.org-id Science en
pubs.org-id Science Research en
pubs.org-id Maurice Wilkins Centre (2010-2014) en
pubs.record-created-at-source-date 2010-09-01 en
pubs.dimensions-id 19363524 en


Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics